These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32715623)

  • 21. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization.
    Boada M; Ortiz P; Anaya F; Hernández I; Muñoz J; Núñez L; Olazarán J; Roca I; Cuberas G; Tárraga L; Buendia M; Pla RP; Ferrer I; Páez A
    Drug News Perspect; 2009; 22(6):325-39. PubMed ID: 19771322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study.
    Wang J; Guo X; Lu W; Liu J; Zhang H; Quan Q; Su H; Ma L; Gao F; Qu Q
    J Alzheimers Dis; 2021; 80(2):673-681. PubMed ID: 33579850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
    Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
    J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's disease progression by geographical region in a clinical trial setting.
    Henley DB; Dowsett SA; Chen YF; Liu-Seifert H; Grill JD; Doody RS; Aisen P; Raman R; Miller DS; Hake AM; Cummings J
    Alzheimers Res Ther; 2015; 7(1):43. PubMed ID: 26120369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease.
    Gold M
    J Clin Psychiatry; 2007 Mar; 68(3):430-8. PubMed ID: 17388715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial.
    Akhondzadeh S; Noroozian M; Mohammadi M; Ohadinia S; Jamshidi AH; Khani M
    J Clin Pharm Ther; 2003 Feb; 28(1):53-9. PubMed ID: 12605619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
    PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET).
    Lang FM; Mo Y; Sabbagh M; Solomon P; Boada M; Jones RW; Frisoni GB; Grimmer T; Dubois B; Harnett M; Friedhoff SR; Coslett S; Cummings JL
    Alzheimers Dement (N Y); 2021; 7(1):e12136. PubMed ID: 34095437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.
    Schneider LS; DeKosky ST; Farlow MR; Tariot PN; Hoerr R; Kieser M
    Curr Alzheimer Res; 2005 Dec; 2(5):541-51. PubMed ID: 16375657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, sham-controlled, clinical trial of repetitive transcranial magnetic stimulation for patients with Alzheimer's dementia in Japan.
    Saitoh Y; Hosomi K; Mano T; Takeya Y; Tagami S; Mori N; Matsugi A; Jono Y; Harada H; Yamada T; Miyake A
    Front Aging Neurosci; 2022; 14():993306. PubMed ID: 36313021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
    Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
    Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
    Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
    J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.